LEX Diagnostics
Selma Esseghir is a Senior Reagent Production Scientist at LEX Diagnostics, responsible for setting up a Production Laboratory for lyophilised qPCR products meeting ISO 13 485: 2016 regulations. With previous experience as a Laboratory Manager at PCR Biosystems and roles as a Postdoctoral Research Scientist at The Institute of Cancer Research and Imperial College London, Selma holds a Ph.D in Molecular Biology from the University of Tunis El Manar.
LEX Diagnostics
LEX Diagnostics is a medical device company that specializes in molecular diagnostics for primary care. Having solved the PCR cost problem, LEX focuses tightly on nasal and oral samples, and on viral pathogens, to avoid the other high-cost elements of traditional molecular diagnostic products. LEX Diagnostics is a spin-out from TTP plc, atechnology development company in the life science and medical device sector. The origins of the LEX technology lie in an internal R&D project to reduce the time it takes to get a result from a PCR test. It formed a company when it became clear the solution also reduced the cost and size of any diagnostic device using it.LEX Diagnostics was founded in 2020 and is based in Melbourn, United Kingdom.